Healthcare >> CEO Interviews >> February 24, 2003
HANS S. KEIRSTEAD is President and Chief Executive Officer of
Ability Biomedical Corporation and Assistant Professor at the
Reeve-Irvine Research Center at the University of California,
Irvine. He received his PhD from the University of British
Columbia in Canada. His PhD thesis constituted the first
demonstration of functional regeneration of the injured adult
spinal cord, for which he received the Cameron Award for the
outstanding PhD thesis in Canada. This work formed the basis of
several issued worldwide patents as well as the formation of a
company in 1999 which he founded and ran as CEO for 18 months
prior to founding Ability Biomedical Corporation. He conducted
post-doctoral studies at Cambridge University in England
concerning spinal cord injury and multiple sclerosis. Dr.
Keirstead has garnered over US$1.9 million in university research
funding over the past year and routinely advises the California
State Senate. Profile
ANDREW J. RAE is Chief Financial Officer of Ability Biomedical
Corporation. He has a decade of experience in the biotechnology
field, most recently raising $15 million in venture funding as
Vice President, Finance and Corporate Affairs, Active Pass
Pharmaceuticals Inc. Mr. Rae has also served as a Biotechnology
Equities Analyst for Goepel Shields and Partners (now Raymond
James, Canada) and Consultant to Ventures West Management, a
prominent Canadian biotechnology venture capitalist. Profile
Ability Biomedical Corporation is today as a business and as an
organization?
Dr. Keirstead: Ability Biomedical is a private
